2 European Medicines Agency (EMA) ETF recommends updating COVID-19 vaccines to target new JN.1 variant. 30 April 2024. Available at: https://www.ema.europa.eu/en/news/etf-recommends-updating-covid-19- vaccines-target-new-jn1-variant (Accessed 26.06.2024). BioNTech: Media Relations Jasmina Alatovic +49 (0)6131 9084 1513 Media@biontech.de Investor Relations Victoria Meissner, M.D. +1 617 528 8293 Investors@biontech.de ---------- 1 World Health Organization (WHO) Statement on the antigen composition of COVID-1 ...

Designation is based on pre-clinical data and data from an ongoing Phase 1/2 trial for BNT324/DB1311, with antitumor activity and a manageable safety profile demonstrated by preliminary Phase 1/2 clinical data from patients with advanced or metastatic solid tumors1,2 With the Fast Track designation, the development of BNT324/DB-1311 can benefit from more frequent engagement with the U.S. Food and Drug Administration ("FDA") to support development and expedite regulatory review Prostate cancer is the second ...

COPENHAGEN, Denmark, and MAINZ, Germany, June 1, 2024 — Genmab A/S (NASDAQ:GMAB, "Genmab"))) and BioNTech SE (NASDAQ:BNTX, "BioNTech"))) today announced initial data from the ongoing Phase 2 trial (NCT05117242) evaluating acasunlimab (DuoBody-PD-L1x4-1BB), an investigational bispecific antibody also known as GEN1046/BNT311, as monotherapy and in combination with pembrolizumab in patients with PD-L(1)-positive metastatic non-small cell lung cancer ("mNSCLC") who had disease progression following one or more ...

Core Insights - MediLink Therapeutics has announced a strategic collaboration with BioNTech, granting BioNTech an exclusive option for a global license to MediLink's TMALIN® antibody-drug conjugate (ADC) platform for several novel targets [1][2] Group 1: Collaboration Details - MediLink will receive an upfront payment of $25 million and could earn up to $1.8 billion in additional milestone payments, along with tiered royalties on future global annual net sales [2] - MediLink retains the right of first negotiation for future collaborations regarding these ADC product candidates in the Mainland China market and potentially in Hong Kong, Macau, or Taiwan [2] Group 2: Previous Collaborations - The new agreement expands upon a previous collaboration established in October 2023, where MediLink and BioNTech entered into a global license agreement to develop BNT326/YL202, a next-generation anti-HER3 ADC [3] Group 3: Company Overview - MediLink Therapeutics, founded in 2020, focuses on developing conjugated drugs with global competitiveness and has developed the proprietary TMALIN® ADC technology platform [4] - The TMALIN® platform enables the creation of homogeneous ADCs with a high drug-antibody ratio and improved therapeutic window for solid tumors, addressing unmet medical needs [4][5]

A bird flu outbreak could spur demand for vaccines from these key players, but is it likely? Shares of vaccine stocks Moderna (MRNA 0.42%), Novavax (NVAX -3.50%), and BioNTech SE (BNTX -3.23%) rallied this week, appreciating 23.4%, 16.4%, and 9.3%, respectively, through Thursday trading, according to data from S&P Global Market Intelligence. Unlike the COVID-19 pandemic, when the U.S. government subsidized private companies to make the COVID- 19 vaccine, the government actually has a stockpile of H5N1 virus ...

MAINZ, Germany, May 21, 2024 – BioNTech SE (Nasdaq: BNTX, "BioNTech" or "the Company") will present clinical trial data for selected programs from the Company's diversified immuno-oncology pipeline at the American Society of Clinical Oncology ("ASCO") Annual Meeting in Chicago, Illinois, from May 31 to June 4, 2024. Moreover, in support of the Company's ongoing CAR-T cell and individualized mRNA programs, BioNTech will also present epidemiological and real-world data from two observational studies in patien ...

Highlights of BioNTech's updates to be presented at the ASCO Annual Meeting 2024: BioNTech has established a diversified clinical oncology pipeline based on its modular multi-platform approach. The Company is advancing more than 20 clinical programs in unmet medical need solid tumor indications, including mRNA-based immunotherapies, targeted therapies entailing cell therapies and antibody- drug conjugates (ADCs), and novel immunomodulators. These candidates are currently being evaluated in more than 30 clin ...

Planegg/Martinsried, May 21, 2024. Medigene AG (Medigene or the "Company", FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of differentiated T cell immunotherapies for solid tumors and BioNTech SE (NASDAQ:BNTX, "BioNTech"))) have announced that their collaboration to advance T cell receptor (TCR) immunotherapies against cancer will extend beyond the initial three-year term outlined at the signing of the agreement in February 2022. This extension will ...

MAINZ, Germany, May 17, 2024 (GLOBE NEWSWIRE) — BioNTech SE (Nasdaq: BNTX, "BioNTech" or the "Company") held its Annual General Meeting ("AGM") today, May 17, 2024. A total of 87.51 per cent of the share capital was represented at the virtual assembly. There were 14 items on the agenda of the AGM. All resolutions proposed on the agenda items put to the vote at today's AGM were approved by a large majority of the shareholders. "The past few years marked a leap in competence for BioNTech," said Helmut Jeggle, ...

| --- | --- | --- | --- | --- | |--------------------------------------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | st | | | | | | 1 Quarter 2024 | | | | | | | | | | | | Financial Results & Corporate Update | | | | | | | | | | | | May 6, 2024 | | | | | | | | | | | 2 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation ...